Global Venous Thromboembolism Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 204 pages | ID: G6BE47C3689EN
Precision Business Insights (PBI)

Abstracts

Global Venous Thromboembolism Treatment Market

Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism. Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins.

The venous thromboembolism treatment market is growing at a significant CAGR due to increase in geriatric population. A rise in the government expenditure, increase in the incidence of venous thromboembolism are fuelling the venous thromboembolism treatment market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period. However, a high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism treatment market over the forecast period.

The venous thromboembolism treatment market is segmented on the basis of drug type, disease type, and distribution channel

Based on drug type, venous thromboembolism treatment market is segmented into the following:

• Factor Xa inhibitors
• Thrombolytic therapy
• Plasminogen activators
• Fondaparinux
• Dabigatran
• Warfarin

Based on disease type, the venous thromboembolism treatment market is segmented into the following:

• Deep vein thrombosis
• Pulmonary embolism

Based on distribution channel, the venous thromboembolism treatment market is segmented into the following:

• Hospital pharmacies
• Online Pharmacies
• Retail pharmacies

The growth of venous thromboembolism treatment market is due to rise in prevalence of venous thromboembolism (According to the International Society of Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism treatment market share. For instance, in March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients. Similarly, in May 2011, Eliquis (apixaban) Approved In Europe for preventing venous thromboembolism after elective knee or hip replacement. Also, in January 2015, Bayer forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.

Geographically, venous thromboembolism treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. North America anticipated to hold the largest share in the venous thromboembolism treatment market owing to increase in the incidence (According to U.S. International Society on Thrombosis and Haemostasis, Inc. (ISTH) there are around 100,000 to 300,000 venous thromboembolism related deaths reported annually) and prevalence rate, rise in demand for advanced treatments, an increase in aging population in the North America region. Moreover, a rise in healthcare expenditure, growing awareness regarding the disease and treatments, and increase in prevalence rate in the Europe region drives the venous thromboembolism treatment market over the forecast period. Asia-Pacific is a key region for venous thromboembolism treatment market due to increase in the government expenditure and healthcare infrastructure. However, a high cost of the venous thromboembolism treatment and low awareness regarding venous thromboembolism treatment among key stakeholders are the key factors hindering the venous thromboembolism treatment market growth in Latin America and the Middle East and Africa regions.

Some of the players in venous thromboembolism treatment market are Sanofi (France), Pfizer Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), Bristol Myers Squibb (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co. (U.S.), Astellas Pharma Inc. (Japan), Sawai Pharmaceuticals Co. Ltd. (U.S.), Abbott Laboratories (U.S.), Wockhardt Ltd (India), Bayer AG (Germany), and Dupont (U.S.) to name a few

In June 2017, U.S. FDA granted priority review of Xarelto (Rivaroxaban) NDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism

In February 2016, Bristol Myers Squibb and Pfizer, Inc. collaborated with Portola Pharmaceuticals Inc. for the development and commercialization of investigational drug Andexanet Alfa in the Japan

In May 2015, Bayer’s Xarelto approved in China for stroke prevention in patients with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis

Report Outline:

• The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments, and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL VENOUS THROMBOEMBOLISM MARKET INTRODUCTION

2.1. Global Venous Thromboembolism Market – Taxonomy
2.2. Global Venous Thromboembolism Market –Definitions
  2.2.1. Drug Type
  2.2.2. Disease Type
  2.2.3. End User

3. GLOBAL VENOUS THROMBOEMBOLISM MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Venous Thromboembolism Market Dynamics – Factors Impact Analysis
3.6. Global Venous Thromboembolism Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Venous Thromboembolism Market – Product Innovations

4. GLOBAL VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL VENOUS THROMBOEMBOLISM MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Factor Xa inhibitors
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Thrombolytic therapy
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Plasminogen activators
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Fondaparinux
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis
5.5. Dabigatran
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.5.3. Market Opportunity Analysis
5.6. Warfarin
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.6.3. Market Opportunity Analysis

6. GLOBAL VENOUS THROMBOEMBOLISM MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Deep Vein Thrombosis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Pulmonary Embolism
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis

7. GLOBAL VENOUS THROMBOEMBOLISM MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital pharmacies
7.2. Online Pharmacies
7.3. Retail pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL VENOUS THROMBOEMBOLISM MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Venous Thromboembolism Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2017 – 2023

9. NORTH AMERICA VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Factor Xa inhibitors
    9.1.1.2. Thrombolytic therapy
    9.1.1.3. Plasminogen activators
    9.1.1.4. Fondaparinux
    9.1.1.5. Dabigatran
    9.1.1.6. Warfarin
  9.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.2.1. Deep vein thrombosis
    9.1.2.2. Pulmonary embolism
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Online Pharmacies
    9.1.3.3. Retail Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Venous Thromboembolism Market Dynamics – Trends

10. EUROPE VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Factor Xa inhibitors
    10.1.1.2. Thrombolytic therapy
    10.1.1.3. Plasminogen activators
    10.1.1.4. Fondaparinux
    10.1.1.5. Dabigatran
    10.1.1.6. Warfarin
  10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.2.1. Deep vein thrombosis
    10.1.2.2. Pulmonary embolism
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Online Pharmacies
    10.1.3.3. Retail Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Venous Thromboembolism Market Dynamics – Trends

11. ASIA-PACIFIC VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Factor Xa inhibitors
    11.1.1.2. Thrombolytic therapy
    11.1.1.3. Plasminogen activators
    11.1.1.4. Fondaparinux
    11.1.1.5. Dabigatran
    11.1.1.6. Warfarin
  11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.2.1. Deep vein thrombosis
    11.1.2.2. Pulmonary embolism
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Online Pharmacies
    11.1.3.3. Retail Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2017 – 2023
  11.1.6. Europe Venous Thromboembolism Market Dynamics – Trends

12. LATIN AMERICA VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Factor Xa inhibitors
    12.1.1.2. Thrombolytic therapy
    12.1.1.3. Plasminogen activators
    12.1.1.4. Fondaparinux
    12.1.1.5. Dabigatran
    12.1.1.6. Warfarin
  12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.2.1. Deep vein thrombosis
    12.1.2.2. Pulmonary embolism
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Online Pharmacies
    12.1.3.3. Retail Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Venous Thromboembolism Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA VENOUS THROMBOEMBOLISM MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Factor Xa inhibitors
    13.1.1.2. Thrombolytic therapy
    13.1.1.3. Plasminogen activators
    13.1.1.4. Fondaparinux
    13.1.1.5. Dabigatran
    13.1.1.6. Warfarin
  13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.2.1. Deep vein thrombosis
    13.1.2.2. Pulmonary embolism
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Online Pharmacies
    13.1.3.3. Retail Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Venous Thromboembolism Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Sanofi (France)
  14.2.2. Pfizer Inc. (U.S.)
  14.2.3. Daiichi Sankyo Co. Ltd. (Japan)
  14.2.4. Bristol Myers Squibb (U.S.)
  14.2.5. Johnson & Johnson Services, Inc. (U.S.)
  14.2.6. AbbVie Inc. (U.S.)
  14.2.7. Merck & Co. (U.S.)
  14.2.8. Astellas Pharma Inc. (Japan)
  14.2.9. Sawai Pharmaceuticals Co. Ltd. (U.S.)
  14.2.10. Abbott Laboratories (U.S.)
  14.2.11. Wockhardt Ltd (India)
  14.2.12. Bayer AG (Germany)
  14.2.13. Dupont Pharm Co. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS